Cargando…
Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma
Adjuvant therapy is one of the major advances in the treatment of breast carcinoma patients – but do all patients need it? New predictive markers, which are able to save breast carcinoma patients from the most toxic adjuvant therapies, are still needed. The expression of matrix metalloproteinases (M...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2003
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394290/ https://www.ncbi.nlm.nih.gov/pubmed/14520459 http://dx.doi.org/10.1038/sj.bjc.6601238 |